News
-
The COPD Foundation has partnered with ENA Respiratory for development of ENA’s INNA-051 pegylated TLR2/6 agonist pan-antiviral nasal spray in patients with chronic lung disease, the company said. In June 2021, ENA Respiratory announced that… Read more . . .
-
CDMO Kindeva Drug Delivery has announced that it will invest in a second MDI manufacturing line capable of filling lower global warming potential (GWP) propellants such as HFA 152a and HFO 1234ze in response to… Read more . . .
-
Ferrer has acquired the rights to distribute United Therapeutics’ Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) outside of the US, Canada, Israel, Japan, and China. Terms of the… Read more . . .
-
Gilbert Technologies, which is developing a soft mist inhaler device based on electrohydrodynamic atomization technology, announced that Scott Fleming will take on the role of Chief Commercial Officer. Fleming, who has been the company’s Technology… Read more . . .
-
CDMO Hovione has announced that Jean-Luc Herbeaux will succeed Guy Villax as CEO of Hovione as of April 1, 2022. Herbeaux joined Hovione as Chief Operating Officer in 2020 after having served in various executive… Read more . . .
-
TFF Pharmaceuticals said that in vitro studies have demonstrated that the company’s inhaled niclosamide candidate completely inhibits the Omicron variant of SARS-CoV-2 at a concentration of 1 μM, noting that both nirmatrelvir (Paxlovid) and molnupiravir have been… Read more . . .
-
AstraZeneca has announced a partnership with Honeywell for development of lower global warming potential MDIs using HFO-1234ze as a propellant. The company said that Breztri budesonide/ glycopyrronium/ formoterol fumarate is the first product it plans… Read more . . .
-
According to Armata Pharmaceuticals, the FDA has cleared the company’s IND for a clinical trial of AP-PA02, an inhaled phage cocktail, in non-cystic fibrosis bronchiectasis (NCFB), and the company plans to initiate a Phase 2… Read more . . .
-
Glenmark Pharmaceuticals said that its subsidiary Glenmark Pharmaceuticals Columbia has acquired exclusive rights to commercialize AstraZeneca’s Pulmicort Respules budesonide inhalation suspension for the treatment of asthma in Columbia. AstraZeneca will manufacture the inhalation suspension and… Read more . . .
-
Virpax Pharmaceuticals said that preclinical studies of the company’s Envelta (NES100) enkephalin nasal spray have not identified any toxicology issues in either rats or dogs. The company said that the results support further development of… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.